CTOs on the Move

Neomorph

www.neomorph.com

 
Neomorph is a venture backed biotechnology company based in San Diego, California.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Neomorph raised $109M on 12/22/2020

Similar Companies

Human Genome Sciences

Human Genome Sciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Capital Genomix (US Headquarters)

Capital Genomix (US Headquarters) is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ichnos

Start-up spirit. Experienced leadership. A mission of change. Ichnos (`īk-nōz) Sciences—a name taken from an ancient Greek word for “footprint”—is shifting how the world thinks about innovation in medicine. With a new approach to the research, discovery, and development of breakthrough therapies in oncology, we`re forging a new path forward. We aim to treat disease holistically, seeking to provide curative therapies that extend human life and improve quality of life. Science SHIFTED…from now on. Headquartered in the NYC metro area with additional teams in Switzerland, ours is a mission rooted in purpose and aimed at progress. Ichnos Sciences is fast-paced, forward-looking and visionary—a company where science, creativity, and a diversity of ideas thrive. We move quickly and nimbly, working together, challenging and supporting one another and ourselves to go further, look deeper, take scientific risks, shift perspectives, and drive forward the scientific advances that will leave an imprint on the world around us. At Ichnos Sciences, we dare to imagine a world where cure is possible. And we invite you to join us. Because cure is possible.

Sports Performance International

Sports Performance International is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.